AusVaxSafety, together with the Australian Government Department of Health and Aged Care, state and territory health departments and the Therapeutic Goods Administration (TGA), is conducting long-term follow-up surveillance of individuals who experienced an adverse event of special interest (AESI) following COVID-19 vaccination. 

The program will help us gain a greater understanding of the characteristics, progress and outcomes of individuals affected by AESIs following COVID-19 vaccination. Data captured from the program will provide clinicians treating patients affected by these AESIs with important clinical management information and will inform future government and expert advisory body guidance around COVID-19 vaccination in Australia.

How it works

What is an adverse event of special interest?

An AESI is a defined condition or event that occurs in some individuals following immunisation, that has the potential to be causally associated with a vaccine product. Examples of AESIs include anaphylaxis, myocarditis and more recently TTS. AESIs need to be carefully monitored and confirmed by further research studies, which is what the AusVaxSafety AESI follow-up program will help contribute to in an Australian setting.

AESIs currently being investigated 

Click on the tiles below to find out more about each AESI being investigated.

Thrombosis with thrombocytopenia syndrome (TTS)

Myocarditis